Bone Marrow Biopsy — Marrow Tissue Sampling

A bone marrow examination consists of two distinct components performed during the same procedure: an aspiration and a trephine core biopsy. The aspirate collects the liquid marrow suspension containing loose haematopoietic cells, which is ideal for cytological morphology, immunophenotyping, and cytogenetic analysis. The core biopsy removes a solid cylindrical plug of intact bone and marrow framework, preserving cellular spatial relationships, overall cellularity, and the presence of fibrosis or focal architectural disruption.

Pathologists examine the specimen using specialised histology stains, immunohistochemistry, and molecular profiling to determine the marrow's cellular density, lineage maturation, and neoplastic infiltration. The procedure is vital for differentiating benign causes of bone marrow failure from malignant processes, assessing treatment responses at the cellular level, and identifying genomic alterations that guide modern precision oncology.

Accurate cancer staging and classification hinge on high-quality tissue analysis. For numerous haematological conditions, a bone marrow biopsy represents the definitive diagnostic procedure. Without it, clinicians cannot establish accurate subtype diagnoses, identify risk-stratifying mutations, or confirm whether disease has invaded marrow spaces. In post-treatment settings, serial biopsies confirm deep remissions, assess residual cellular disease, and alert doctors to early relapses before they cause physical illness.

The collected marrow sample is subjected to multiple complementary assessments: light microscopy with Wright-Giemsa and haematoxylin-eosin stains, flow cytometry for CD markers, cytogenetic karyotyping, FISH for chromosomal rearrangements, and next-generation sequencing gene panels. Liquid aspirate samples also serve to evaluate minimal residual disease using highly sensitive polymerase chain reaction (PCR) assays.

Bone marrow biopsies are crucial in diagnosing and managing acute and chronic leukaemias, Hodgkin and non-Hodgkin lymphomas, and multiple myeloma. They are also conducted to stage advanced solid tumours with a propensity for bone marrow involvement, such as neuroblastoma, prostate cancer, small cell lung cancer, and metastatic breast cancer.

Biopsy findings directly govern whether a patient requires induction chemotherapy, targeted oral therapy, or allogeneic stem cell transplantation. Discovering specific genetic aberrations within the marrow cells, such as PML-RARA in acute promyelocytic leukaemia or BCR-ABL1 in CML, allows the selection of targeted therapies that produce excellent disease control without standard cytotoxic chemotherapy.